Keros Therapeutics ( NASDAQ: KROS ) has appointed Jasbir S. Seehra, Chief Executive Officer, as Chair of the Board, effective July 1, 2024. Seehra will succeed current Chair Carl L.
Gordon, who will remain an active Board member. Jean-Jacques Bienaimé will serve as the Lead Independent Director of the Board, effective July 1, 2024. Additionally, Christopher Rovaldi has been promoted to President, effective July 1, 2024.
Rovaldi will also continue serving as Chief Operating Officer of Keros. Source: Press Release More on Keros Therapeutics Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers Seeking Alpha’s Quant Rating on Keros Therapeutics Historical earnings data for Keros Therapeutics Financial information for Keros Therapeutics.